<DOC>
	<DOCNO>NCT00876395</DOCNO>
	<brief_summary>The purpose Phase III study confirm value add everolimus weekly paclitaxel trastuzumab treatment HER2-overexpressing metastatic breast cancer .</brief_summary>
	<brief_title>Everolimus Combination With Trastuzumab Paclitaxel Treatment HER2 Positive Locally Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Adult Women ( ≥ 18 year old ) . Histologically cytologically confirm invasive breast carcinoma local recurrence radiological evidence metastatic disease . Must least one lesion accurately measure bone lesion absence measurable disease . HER2+ patient local laboratory testing ( IHC 3+ stain situ hybridization positive ) . Prior trastuzumab and/or chemotherapy ( taxanes include ) neoadjuvant adjuvant treatment allow discontinue &gt; 12 month prior randomization . Prior treatment breast cancer endocrine therapy ( adjuvant metastatic setting ) allow discontinue randomization . Patients treat bisphosphonates entry start bisphosphonates study may continue therapy protocol treatment . Documentation negative pregnancy test . Prior mTOR inhibitor treatment cancer . Other anticancer therapy locally advance metastatic breast cancer except prior hormonal therapy . Patients nonmeasurable lesion bone metastasis ( e.g . pleural effusion , ascites , etc ) . Radiotherapy ≥ 25 % bone marrow within 4 week prior randomization History central nervous system metastasis . Impairment gastrointestinal ( GI ) function GI disease active ulceration upper gastrointestinal tract . Serious peripheral neuropathy . Cardiac disease dysfunction . Uncontrolled hypertension . HIV . Pregnant , Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>HER2+</keyword>
	<keyword>mTOR</keyword>
	<keyword>everolimus</keyword>
	<keyword>RAD001</keyword>
	<keyword>first line</keyword>
	<keyword>metastatic</keyword>
	<keyword>locally advanced</keyword>
</DOC>